EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

The Role of p-VEGFR2/p-AKT and HDAC1 in Apatinib-associated Inhibition of Gallbladder Cancer Cell Growth

Wei Huang, Yanmin Pang, Wenmei Zhao, Liang’e Xia, Luting Wang, Yingde Nong, Kai Xiao, Yichong Ning

Exploratory Research and Hypothesis in Medicine · 30.07.2026 · 11 (3)

DOI: 10.14218/jerp.2025.00068 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Exploratory Research and Hypothesis in Medicine, online erschienen am 29.06.2026. Verfasst von Wei Huang und 7 weiteren Autor:innen. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Luteolin is a dietary flavonoid widely distributed in fruits and vegetables. It has attracted substantial preclinical interest due to its pleiotropic hepatoprotective effects against hepatic steatosis, inflammation, fibrosis, and hepatocellular carcinoma. By reviewing data from in vitro and in vivo studies, this review comprehensively synthesizes the full spectrum of liver-directed pharmacology of luteolin, covering metabolic and toxic liver injury, fibrosis, cancer, and viral hepatitis, while critically mapping each mechanism to specific disease contexts and systematically identifying the key challenges limiting its clinical translation. The underlying mechanisms of luteolin action involve activation of Nrf2-mediated antioxidant defense, suppression of NF-κB- and NLRP3-driven inflammatory responses, inhibition of hepatic stellate cell activation via the TGF-β/Smad and STAT3 pathways, and regulation of metabolic homeostasis through liver X receptor (LXR)/SREBP-1c and AMPK signaling. Despite well-characterized mechanisms in preclinical models, several critical gaps hinder its clinical translation: (1) Rigorous randomized controlled trials in well-defined patient populations are scarce, with only one combination supplement study reported. (2) The relative contribution of luteolin metabolites to its overall bioactivity remains poorly understood, even though derivatives such as luteolin-7-diglucuronide exhibit distinct pharmacological properties. Cell-type-specific delivery systems, which show promise in preclinical fibrosis and cancer models, have not been evaluated clinically. (3) Systematic studies on the synergistic effects of luteolin with standard-of-care drugs remain largely exploratory. Overall, luteolin is a promising multi-target nutraceutical for liver diseases, and its clinical translation requires optimized delivery strategies, investigation of metabolite activity, and well-designed human clinical trials.

Zitieren

APA

Huang, W., Pang, Y., Zhao, W., Xia, L., Wang, L., Nong, Y., Xiao, K., & Ning, Y. (2026). The Role of p-VEGFR2/p-AKT and HDAC1 in Apatinib-associated Inhibition of Gallbladder Cancer Cell Growth. Exploratory Research and Hypothesis in Medicine, 11(3). https://doi.org/10.14218/jerp.2025.00068

Vancouver

Huang W, Pang Y, Zhao W, Xia L, Wang L, Nong Y, et al. The Role of p-VEGFR2/p-AKT and HDAC1 in Apatinib-associated Inhibition of Gallbladder Cancer Cell Growth. Exploratory Research and Hypothesis in Medicine. 2026;11(3). doi:10.14218/jerp.2025.00068

BibTeX
@article{Huang2026,
  author = {Huang, Wei and Pang, Yanmin and Zhao, Wenmei and Xia, Liang’e and Wang, Luting and Nong, Yingde and Xiao, Kai and Ning, Yichong},
  title = {The Role of p-VEGFR2/p-AKT and HDAC1 in Apatinib-associated Inhibition of Gallbladder Cancer Cell Growth},
  journal = {Exploratory Research and Hypothesis in Medicine},
  year = {2026},
  volume = {11},
  number = {3},
  doi = {10.14218/jerp.2025.00068}
}
Kostenlos starten →